Celldex Therapeutics, Inc. (CLDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.68+0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CLDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -26.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CLDX — CFO transition
Dated 2026-07-15
Chief Financial Officer — Sam Martin: Sam Martin plans to retire as Chief Financial Officer, with a transition period until March 31, 2027.
Why it matters: The trend in operating losses shows if management controls costs well. This affects future funding needs.
Worry ifOperating losses decrease from -$84.4M in Q1 to less than -$70M in Q2.
Less concerning ifOperating losses increase beyond -$84.4M in Q2.
Why it matters: The CFO change could affect financial plans. It may also impact management stability.
Watch forThe new CFO should share clear financial plans.
Also watch forConfusion or problems during the CFO change.
Why it matters: Topline data will show if barzolvolimab is effective for chronic spontaneous urticaria. This could lead to a BLA submission in 2027.
Supportive ifData from the Phase 3 CSU studies shows good results.
Worry ifData from the Phase 3 CSU studies shows no good results.
Why it matters: If the sector shows renewed growth, it could benefit Celldex's market position.
Supportive ifSector revenue growth reported above 10% year over year.
Worry ifSector revenue growth reported below 5% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$149 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $439 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,423 loss on $10,000 · 24.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good results could help expand into more uses. This would improve the product pipeline.
Supportive ifResults from the Phase 1 trial of CDX-622 show significant reductions in serum tryptase.
Worry ifResults from the Phase 1 trial show no significant reduction in serum tryptase.
Why it matters: Updates will show if Celldex has enough funds for operations and trials.
Supportive ifCash position shows an increase from the public offering, ensuring funding through 2028.
Worry ifCash position drops a lot, raising worries about future funding.
Why it matters: Good results could improve the barzolvolimab profile. This may help its market potential.
Supportive ifData from the Phase 2 prurigo nodularis study shows strong results.
Worry ifData from the Phase 2 prurigo nodularis study shows no strong results.
Why it matters: Results will show how safe and effective the drug is for asthma. This will affect future plans.
Watch forPositive results from the Phase 1 trial show good safety and effects in asthma patients.
Also watch forResults show no big safety issues or effects.
Why it matters: Topline results will show how well the drug works for chronic spontaneous urticaria. This could help with a future BLA filing.
Supportive ifTopline data from the Phase 3 trials show good results.
Worry ifTopline data reveal that the trials did not meet primary endpoints.
Why it matters: If cash reserves go down, it raises worries about the company’s ability to run.
Worry ifCash reserves reported below $100M.
Less concerning ifCash reserves remain above $100M.
Why it matters: Updates on cash reserves show if the company can keep running. This is key for investor trust.
Supportive ifManagement says they have enough cash to run the business until 2028.
Worry ifCash reserves will not last to cover operations until 2028.